These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 19955362)

  • 1. Dopaminergic drugs modulate learning rates and perseveration in Parkinson's patients in a dynamic foraging task.
    Rutledge RB; Lazzaro SC; Lau B; Myers CE; Gluck MA; Glimcher PW
    J Neurosci; 2009 Dec; 29(48):15104-14. PubMed ID: 19955362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson's disease.
    McCoy B; Jahfari S; Engels G; Knapen T; Theeuwes J
    Brain; 2019 Nov; 142(11):3605-3620. PubMed ID: 31603493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct effects of apathy and dopamine on effort-based decision-making in Parkinson's disease.
    Le Heron C; Plant O; Manohar S; Ang YS; Jackson M; Lennox G; Hu MT; Husain M
    Brain; 2018 May; 141(5):1455-1469. PubMed ID: 29672668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of dopaminergic medication on dynamic decision making in Parkinson's disease.
    Osman M; Ryterska A; Karimi K; Tu L; Obeso I; Speekenbrink M; Jahanshahi M
    Neuropsychologia; 2014 Jan; 53():157-64. PubMed ID: 24269857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine is associated with prioritization of reward-associated memories in Parkinson's disease.
    Sharp ME; Duncan K; Foerde K; Shohamy D
    Brain; 2020 Aug; 143(8):2519-2531. PubMed ID: 32844197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson's disease: does the therapy-dose matter?
    Torta DM; Castelli L; Zibetti M; Lopiano L; Geminiani G
    Brain Cogn; 2009 Nov; 71(2):84-91. PubMed ID: 19442427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease.
    Shiner T; Seymour B; Wunderlich K; Hill C; Bhatia KP; Dayan P; Dolan RJ
    Brain; 2012 Jun; 135(Pt 6):1871-83. PubMed ID: 22508958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Selective Role for Dopamine in Learning to Maximize Reward But Not to Minimize Effort: Evidence from Patients with Parkinson's Disease.
    Skvortsova V; Degos B; Welter ML; Vidailhet M; Pessiglione M
    J Neurosci; 2017 Jun; 37(25):6087-6097. PubMed ID: 28539420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive states influence dopamine-driven aberrant learning in Parkinson's disease.
    Cavanagh JF; Mueller AA; Brown DR; Janowich JR; Story-Remer JH; Wegele A; Richardson SP
    Cortex; 2017 May; 90():115-124. PubMed ID: 28384481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine restores cognitive motivation in Parkinson's disease.
    McGuigan S; Zhou SH; Brosnan MB; Thyagarajan D; Bellgrove MA; Chong TT
    Brain; 2019 Mar; 142(3):719-732. PubMed ID: 30689734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dopamine on reinforcement learning and consolidation in Parkinson's disease.
    Grogan JP; Tsivos D; Smith L; Knight BE; Bogacz R; Whone A; Coulthard EJ
    Elife; 2017 Jul; 6():. PubMed ID: 28691905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose dependent dopaminergic modulation of reward-based learning in Parkinson's disease.
    van Wouwe NC; Ridderinkhof KR; Band GP; van den Wildenberg WP; Wylie SA
    Neuropsychologia; 2012 Apr; 50(5):583-91. PubMed ID: 22223079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner.
    Cherkasova MV; Corrow JC; Taylor A; Yeung SC; Stubbs JL; McKeown MJ; Appel-Cresswell S; Stoessl AJ; Barton JJS
    Parkinsonism Relat Disord; 2019 Sep; 66():189-194. PubMed ID: 31473085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impulse control disorders in Parkinson's disease are associated with dysfunction in stimulus valuation but not action valuation.
    Piray P; Zeighami Y; Bahrami F; Eissa AM; Hewedi DH; Moustafa AA
    J Neurosci; 2014 Jun; 34(23):7814-24. PubMed ID: 24899705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microstimulation of the human substantia nigra alters reinforcement learning.
    Ramayya AG; Misra A; Baltuch GH; Kahana MJ
    J Neurosci; 2014 May; 34(20):6887-95. PubMed ID: 24828643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
    Shohamy D; Myers CE; Grossman S; Sage J; Gluck MA
    Behav Brain Res; 2005 Jan; 156(2):191-9. PubMed ID: 15582105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making.
    Groman SM; Smith NJ; Petrullli JR; Massi B; Chen L; Ropchan J; Huang Y; Lee D; Morris ED; Taylor JR
    J Neurosci; 2016 Jun; 36(25):6732-41. PubMed ID: 27335404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Iowa Gambling Task in Parkinson's disease: A meta-analysis on effects of disease and medication.
    Evens R; Hoefler M; Biber K; Lueken U
    Neuropsychologia; 2016 Oct; 91():163-172. PubMed ID: 27475264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human substantia nigra neurons encode unexpected financial rewards.
    Zaghloul KA; Blanco JA; Weidemann CT; McGill K; Jaggi JL; Baltuch GH; Kahana MJ
    Science; 2009 Mar; 323(5920):1496-9. PubMed ID: 19286561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.